The First Test To Detect Preeclampsia From Thermo Fisher Gets FDA Approval
Portfolio Pulse from Vandana Singh
The FDA has approved Thermo Fisher Scientific's blood test for preeclampsia, a pregnancy-related illness. The test is the first blood-based biomarker immunoassay to receive breakthrough designation and clearance for risk assessment and clinical management of preeclampsia.
May 19, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Thermo Fisher Scientific's blood test for preeclampsia has received FDA approval, potentially increasing demand for the test and boosting the company's revenues.
The FDA approval of Thermo Fisher's blood test for preeclampsia is a significant milestone for the company. As the first and only blood-based biomarker immunoassay for risk assessment and clinical management of preeclampsia, the test is likely to see increased demand from healthcare providers. This could lead to higher revenues for Thermo Fisher and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100